CAMBRIDGE, England and SAN DIEGO, Jan. 9, 2025 PRNewswire -- DIOSynVax, a clinical-stage biotechnology company developing innovative, broadly protective vaccines, announces the launch of its new portfolio of vaccines, including preventive vaccines against avian, hyper-seasonal and pandemic influenza, and the unveiling of a new advisory board, following the safety of its first coronavirus vaccine in human trials.
The company's avian flu vaccine has demonstrated its effectiveness and safety in animal trials, including on ferrets, and is now ready for human trials. This unique vaccine is designed to elicit a potent and broadly nigeria telegram data protective immune response against a variety of high-risk viruses, including those that may have originated from human avian influenza cases worldwide, which pose a threat to public and global health. As the number of cases of avian influenza infection continues to increase worldwide, and the first death from the virus has been reported in the United States source.
Washingtonposthealth20250106bird-flu-first-human-death-us , countries are actively preparing for a possible outbreak of avian influenza in humans. Source: Optimized Synthetic Vaccine DIOSynVax technology strategically applies artificial intelligence AI to accelerate the development of safer and more effective vaccines to address current challenges and provide smarter solutions for future threats.